Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirvetuximab soravtansine (Primary)
  • Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms IMGN853-0401
  • Sponsors ImmunoGen

    • Most Recent Events

    • 28 Oct 2022 According to an ImmunoGen media release, retrospective pooled analysis from Phase 1 IMGN853-0401 trial, the Phase 3 FORWARD I trial, and the Phase 3 SORAYA trials were presented at the 23rd Congress of the European Society of Gynaecological Oncology (ESGO).
    • 28 Oct 2022 Retrospective pooled analysis from Phase 1 IMGN853-0401 trial, the Phase 3 FORWARD I trial, and the Phase 3 SORAYA trials are presented in an ImmunoGen media release.
    • 13 Sep 2022 Results of Population pharmacokinetic (PK) analysis Analysis from 3 studies(NCT01609556, NCT02631876, NCT04296890) of mirvetuximab soravtansine (MIRV) in patients with folate receptor (FRalpha)-positive cancer presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top